Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Corbeil Essonnes – page 111

3 332 clinical trials in Corbeil Essonnes, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Corbeil Essonnes at a glance
3 332
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 332 trials in Corbeil Essonnes

Open in trial search

Transitional cell carcinoma+1

Not yet recruiting

Phase 3 Study of trastuzumab brengitecan versus platinum‑based chemotherapy in adults with HER2‑positive metastatic urothelial cancer after anti‑PD‑(L)1 therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Systimmune Inc.

Facioscapulohumeral muscular dystrophy

Not yet recruiting

Phase 2 Study of Apitegromab in Patients with Facioscapulohumeral Muscular Dystrophy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Apitegromab
  • Sponsor:Scholar Rock Inc.

Cutaneous sarcoidosis

Not yet recruiting

A Phase 2/3 Study of the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous Sarcoidosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Priovant Therapeutics Inc.

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Reducing abemaciclib, palbociclib and ribociclib after complete response in HER2‑negative metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Unicancer

Lichen planus

Not yet recruiting

Efficacy and safety of GIA632 versus placebo in adults with moderate to severe cutaneous lichen planus

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Congenital growth hormone deficiency

Not yet recruiting

Study of Daily Oral Ibutamoren Mesilate in Treatment‑Naïve Prepubertal Children with Growth Hormone Deficiency

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ibutamoren Mesilate
  • Sponsor:Lumos Pharma LLC

Avian influenza

Not yet recruiting

Immunogenicity and safety of intradermal zoonotic influenza vaccine (H5N8) compared with intramuscular administration in adults 40–80 years with avian influenza

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:INFLUENZA A/ASTRAKHAN/3212/2020 (H5N8)-LIKE STRAIN (CBER-RG8A) (CLADE 2.3.4.4B)
  • Sponsor:University Of Antwerp

Neoplasm malignant

Not yet recruiting

Phase 1/2 study of AVZO-023 drug combination in patients with advanced cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Avenzo Therapeutics Inc.

Non-small cell lung cancer

Not yet recruiting

Phase 2 Study of Oral VS-7375 in Adults with Advanced KRAS G12D‑Mutated Non‑Small Cell Lung Cancer Previously Treated

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:GFH375
  • Sponsor:Verastem Inc.

Multifocal motor neuropathy

Not yet recruiting

Phase 1b study of empasiprubart in adults with multifocal motor neuropathy to assess nerve morphology by ultrasound

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Argenx

HIV infection

Not yet recruiting

Study of Baricitinib and Sirolimus to Maintain HIV Infection Control After Antiretroviral Treatment Interruption in Adults

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Baricitinib
  • Sponsor:ANRS Maladies Infectieuses Emergentes

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Corbeil Essonnes

What the registry says about research in the country

01 Diabetes and Metabolic Disorders

Clinical research focusing on novel treatments for Type 1 and Type 2 Diabetes, particularly investigating therapies like tirzepatide for glycemic control and cardiovascular outcomes in patients with obesity and diabetes.

  • Glycemic Control Studies
  • Cardiovascular Risk Management
  • Weight Management Therapies
02 Hematologic Malignancies

Groundbreaking trials in Multiple Myeloma treatment, evaluating combinations of targeted therapies including elranatamab, lenalidomide, and daratumumab for newly diagnosed and relapsed cases.

  • Novel Drug Combinations
  • Maintenance Therapy Optimization
  • Minimal Residual Disease Studies
03 Inflammatory and Autoimmune Conditions

Research examining innovative treatments for Immune Thrombocytopenia, Polymyalgia Rheumatica, and Lupus Nephritis, focusing on targeted therapies and steroid-sparing approaches.

  • Immunotherapy Development
  • Alternative Treatment Strategies
  • Disease Management Protocols
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.